173 related articles for article (PubMed ID: 28008571)
21. Assessment of pathologic prognostic factors in breast core needle biopsies.
Sharifi S; Peterson MK; Baum JK; Raza S; Schnitt SJ
Mod Pathol; 1999 Oct; 12(10):941-5. PubMed ID: 10530557
[TBL] [Abstract][Full Text] [Related]
22. Histological grade as an alternative to the Ki67 labeling index is only available for luminal-type breast cancers.
Hayashi S; Kitada M; Sato K; Matsuda Y; Ishibashi K; Oikawa K; Miyokawa N; Hirata S
Breast Cancer; 2014 Jan; 21(1):47-51. PubMed ID: 22467403
[TBL] [Abstract][Full Text] [Related]
23. Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies.
Romero Q; Bendahl PO; Klintman M; Loman N; Ingvar C; Rydén L; Rose C; Grabau D; Borgquist S
BMC Cancer; 2011 Aug; 11():341. PubMed ID: 21819622
[TBL] [Abstract][Full Text] [Related]
24. Visual assessment of Ki67 at a glance is an easy method to exclude many luminal-type breast cancers from counting 1000 cells.
Hida AI; Oshiro Y; Inoue H; Kawaguchi H; Yamashita N; Moriya T
Breast Cancer; 2015 Mar; 22(2):129-34. PubMed ID: 23543399
[TBL] [Abstract][Full Text] [Related]
25. The region-of-interest size impacts on Ki67 quantification by computer-assisted image analysis in breast cancer.
Christgen M; von Ahsen S; Christgen H; Länger F; Kreipe H
Hum Pathol; 2015 Sep; 46(9):1341-9. PubMed ID: 26206765
[TBL] [Abstract][Full Text] [Related]
26. Analysis of the concordance rates between core needle biopsy and surgical excision in patients with breast cancer.
Ricci MD; Calvano Filho CM; Oliveira Filho HR; Filassi JR; Pinotti JA; Baracat EC
Rev Assoc Med Bras (1992); 2012; 58(5):532-6. PubMed ID: 23090222
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Ki-67 Index in Core Needle Biopsies and Matched Breast Cancer Surgical Specimens.
Ahn S; Lee J; Cho MS; Park S; Sung SH
Arch Pathol Lab Med; 2018 Mar; 142(3):364-368. PubMed ID: 29144790
[TBL] [Abstract][Full Text] [Related]
28. Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 ring study.
Mikami Y; Ueno T; Yoshimura K; Tsuda H; Kurosumi M; Masuda S; Horii R; Toi M; Sasano H
Cancer Sci; 2013 Nov; 104(11):1539-43. PubMed ID: 23905924
[TBL] [Abstract][Full Text] [Related]
29. Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens?
Greer LT; Rosman M; Mylander WC; Hooke J; Kovatich A; Sawyer K; Buras RR; Shriver CD; Tafra L
J Am Coll Surg; 2013 Feb; 216(2):239-51. PubMed ID: 23141136
[TBL] [Abstract][Full Text] [Related]
30. How Reliable Are Gene Expression-Based and Immunohistochemical Biomarkers Assessed on a Core-Needle Biopsy? A Study of Paired Core-Needle Biopsies and Surgical Specimens in Early Breast Cancer.
Saghir H; Veerla S; Malmberg M; Rydén L; Ehinger A; Saal LH; Vallon-Christersson J; Borg Å; Hegardt C; Larsson C; Haidar A; Hedenfalk I; Loman N; Kimbung S
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010992
[TBL] [Abstract][Full Text] [Related]
31. Good staining quality ensuring the reproducibility of Ki67 assessment.
Wang YH; Lai CR; Lien HC; Hsu CY
J Clin Pathol; 2020 Jul; 73(7):413-417. PubMed ID: 31796636
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population.
Chen R; Qi Y; Huang Y; Liu W; Yang R; Zhao X; Wu Y; Li Q; Wang Z; Sun X; Wei B; Chen J
Breast Cancer Res Treat; 2023 Jan; 197(1):189-200. PubMed ID: 36346486
[TBL] [Abstract][Full Text] [Related]
33. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases.
Martínez-Arribas F; Núñez MJ; Piqueras V; Lucas AR; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2002; 22(1A):295-8. PubMed ID: 12017306
[TBL] [Abstract][Full Text] [Related]
34. Concordance between core needle biopsy and surgical excision specimens for tumour hormone receptor profiling according to the 2011 St. Gallen Classification, in clinical practice.
Loubeyre P; Bodmer A; Tille JC; Egger JF; Diebold-Berger S; Copercini M; Rozenholc A; Petignat P; Castiglione M
Breast J; 2013; 19(6):605-10. PubMed ID: 24165313
[TBL] [Abstract][Full Text] [Related]
35. A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method.
Jang MH; Kim HJ; Chung YR; Lee Y; Park SY
PLoS One; 2017; 12(2):e0172031. PubMed ID: 28187177
[TBL] [Abstract][Full Text] [Related]
36. Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer.
Jerjees DA; Alabdullah M; Green AR; Alshareeda A; Macmillan RD; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2014 Jun; 145(2):317-30. PubMed ID: 24744091
[TBL] [Abstract][Full Text] [Related]
37. Intratumoral heterogeneity of Ki67 expression in early breast cancers exceeds variability between individual tumours.
Focke CM; Decker T; van Diest PJ
Histopathology; 2016 Nov; 69(5):849-861. PubMed ID: 27270560
[TBL] [Abstract][Full Text] [Related]
38. An intra- and interobserver reproducibility analysis of the Ki-67 proliferation marker assessment on core biopsies of breast cancer patients and its potential clinical implications.
Vörös A; Csörgő E; Nyári T; Cserni G
Pathobiology; 2013; 80(3):111-8. PubMed ID: 23258384
[TBL] [Abstract][Full Text] [Related]
39. Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors.
Nakamura R; Yamamoto N; Shiina N; Miyaki T; Ikebe D; Itami M; Shida T; Miyazaki M
Breast; 2016 Apr; 26():141-7. PubMed ID: 26732051
[TBL] [Abstract][Full Text] [Related]
40. Image-guided core needle biopsy in the diagnosis of malignant lymphoma: comparison with surgical excision biopsy.
Chatani S; Hasegawa T; Kato S; Murata S; Sato Y; Yamaura H; Yamamoto K; Yatabe Y; Inaba Y
Eur J Radiol; 2020 Jun; 127():108990. PubMed ID: 32304929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
